Treatment Options for Community-Acquired Pneumonia
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Recruiting
Phase 3Interventional Study
Community-acquired Pneumonia, Influenza, COVID-19
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
20,000 (estimated)
Sponsor
UMC Utrecht · Other
Who this trial is looking for
This trial is looking for adults in intensive care with severe community-acquired pneumonia. Participants will receive various treatments to see what helps them improve.
Are You a Good Fit for This Trial?
You may be able to join if
I am an adult patient admitted to the ICU for severe community-acquired pneumonia within the last 48 hours.
I have symptoms of a lower respiratory tract infection.
I have new evidence of lung problems from X-rays or scans.
I need help with breathing support, like a ventilator.
I am receiving medications to support my blood pressure or heart function.
You may not be able to join if
I have been in a healthcare facility in the last 30 days before this illness.
I live in a nursing home or long-term care facility.
I am expected to die within the next 24 hours and am not receiving full active treatment.
I participated in this trial in the last 90 days.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.
The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia.
In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in …
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.
The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia.
In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19.
REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
REMAP-CAP PLATFORM INCLUSION CRITERIA:
1. Adult patient admitted to an ICU for severe CAP within 48 hours of hospital admission with:
1. symptoms or signs or both that are consistent with lower respiratory tract infection AND
2. Radiological evidence of new onset consolidation (in patients w…
REMAP-CAP PLATFORM INCLUSION CRITERIA:
1. Adult patient admitted to an ICU for severe CAP within 48 hours of hospital admission with:
1. symptoms or signs or both that are consistent with lower respiratory tract infection AND
2. Radiological evidence of new onset consolidation (in patients with pre-existing radiological changes, evidence of new infiltrate)
2. Up to 48 hours after ICU admission, receiving organ support with one or more of:
1. Non-invasive or Invasive ventilatory support;
2. Receiving infusion of vasopressor or inotropes or both
PLATFORM EXCLUSION CRITERIA:
1. Healthcare-associated pneumonia:
1. Prior to this illness, is known to have been an inpatient in any healthcare facility within the last 30 days
2. Resident of a nursing home or long term care facility
2. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
3. Previous participation in this REMAP within the last 90 days
REMAP-COVID PLATFORM INCLUSION CRITERIA
1\. Adult patients (≥ 18 years) admitted to hospital with acute illness due to suspected or proven pandemic infection.
REMAP-COVID PLATFORM EXCLUSION CRITERIA
1. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
2. Patient is expected to be discharged from hospital today or tomorrow
3. More than 14 days have elapsed while admitted to hospital with symptoms of an acute illness due to suspected or proven pandemic infection.
4. Previous participation in this REMAP within the last 90 days
DOMAIN-SPECIFIC ELIGIBLE CRITERIA:
Each domain may have additional eligibility criteria. Refer to the study website for more information (www.remapcap.org).
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.